Results From the CELESTIAL Trial for Patients with Advanced HCC

Ghassan K. Abou-Alfa, MD

Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses results of the CELESTIAL trial. The results were clinically and statistically significant, Abou-Alfa notes. 

Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses results of the CELESTIAL trial. The results were clinically and statistically significant, Abou-Alfa notes.

This randomized phase III trial compared treatment with cabozantinib (Cabometyx) versus a placebo in patients with advanced hepatocellular carcinoma (HCC) who had received a prior sorafenib (Nexavar) treatment. Findings showed a median overall survival (OS) of 10.2 months in the cabozantinib arm versus 8 months in the placebo arm.

There was also a progression-free survival rate over 5 months versus 1.5 months and a response rate of 4% versus 0.4% in the cabozantinib versus placebo arms, respectively. Patients experienced grade 3 and 4 adverse events, but none were unexpected for this drug, says Abou-Alfa.